D01Accepted
Keep all six baseline rates; tighten their labels; add a reference band
Keep every value. Relabel Oncology and Rare disease as Direction from evidence (IQVIA medians 0.1 to 0.2, industry Phase III mean 0.80 in oncology). Cardiovascular stays Evidence-anchored on Khan et al. CNS, Immunology and GI, and Respiratory stay Illustrative: no per-site rate by area was found. Add a reference band to the Build a site chart showing the industry Phase III median of 0.4 (2016 to 2019) and the UK public-trial median of 0.92 to 0.95.
Why, and what it replaced
- Why
- All six values sit inside the published ranges, but most sources are not split by area and mix means with medians, so the honest gain is in the labels and the reference band, not in new values.
- Before
- Oncology 0.35, Cardiovascular 0.3 (Evidence-anchored), CNS and psychiatry 0.45, Immunology and GI 0.3, Respiratory 0.4, Rare disease 0.1 patients per site per month
- Evidence
- Chapter 1, how often recruitment fails, and which statistics to trust
- Chapter 8, the numbers behind the planner: start-up times, screen failure, rates, and site variation
- Chapter 9, the forecasting model: how the sites-needed planner will work
- Decided
- Accepted by Adam Daniels, October 22nd 2026